Your session is about to expire
← Back to Search
Pembrolizumab + Lenvatinib for Uterine Cancer
Study Summary
This trial is testing a new combination therapy for uterine carcinosarcoma and will also look for biomarkers that could predict how well patients will respond to the treatment.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- I have an immune system disorder or have been on immune-weakening drugs recently.My heart's pumping ability is below the normal range.I have been treated for an autoimmune disease in the last 2 years.I have not had significant coughing up of blood or tumor bleeding in the last 2 weeks.I stopped my hormonal therapy for carcinosarcoma at least a week ago.I am 18 years old or older.My cancer is a specific type that affects the uterus or ovaries and has come back or not gone away.I have a condition that affects how my body absorbs nutrients.My uterine or ovarian cancer is classified as MSS, MSI-H, pMMR, or dMMR.I last took PARP inhibitors more than 3 weeks ago.I have been treated with medications targeting the immune system.I am fully active or can carry out light work.I have received a transplant from a donor.I have a severe fistula.I took Bevacizumab, but it was over 3 weeks ago.My uterine or ovarian cancer has a specific genetic feature.I finished my chemotherapy more than 3 weeks ago.I took Parp-inhibitors, but it's been over 3 weeks since my last dose.I have not received a live vaccine in the last 30 days.I have not been treated for another cancer in the last 2 years.I haven't had major heart problems in the last year.I've had one platinum-based chemotherapy and up to three other treatments.I took Bevacizumab, but it was over 3 weeks ago.I have had pneumonitis treated with steroids or have it now.I do not have any unmanaged ongoing illnesses.I have a serious liver condition.I am 18 years old or older.My blood pressure is under control and I haven't changed my blood pressure medication in the last week.You cannot have participated in another experimental drug study within the last 4 weeks before starting this study.I finished my chemotherapy more than 3 weeks ago.I have had one platinum-based chemotherapy and up to three treatments in total.I am HIV-positive, on treatment, and my viral load is undetectable.I have active brain metastases or cancer in the lining of my brain.I am HIV-positive, on effective treatment, and my viral load has been undetectable for the last 6 months.My organs are functioning well, as tested within the last week.I have active tuberculosis.I have been treated with VEGF TKI before.My previous hormone therapy doesn't count as a treatment line.My cancer is a confirmed carcinosarcoma of the uterus or ovary.My previous hormonal therapy doesn't count as a treatment line.I stopped my hormonal therapy for cancer at least a week ago.I have not had radiotherapy in the last 2 weeks.You cannot tolerate the study treatments.
- Group 1: Pembrolizumab With Lenvatinib
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
To what extent has participation been secured for this research project?
"Affirmative. Records on clinicaltrials.gov demonstrate that this medical trial is currently recruiting participants; it was originally published on December 23rd 2021 and most recently updated April 27th 2022. Forty individuals are being enrolled at seven distinct sites."
What maladies have been successfully treated by Pembrolizumab?
"Pembrolizumab is a versatile drug that can treat malignant neoplasms, unresectable melanomas, microsatellite instability high and diseases which have progressed after chemotherapy."
Is there still availability for patients to join this exploration into new treatments?
"Clinicaltrials.gov shows that this medical research is actively seeking participants, having initially been posted on December 23rd 2021 and last updated in April 27th 2022."
How many centers are currently overseeing this trial?
"This experiment is being conducted across seven different medical sites, including Middletown, Rockville Centre and New york. To make the trial more accessible to participants, it may be helpful for them to select the closest available centre."
Have any other experiments explored the effects of Pembrolizumab?
"At present, 1032 studies of the drug Pembrolizumab are underway with 134 at Phase 3. Most trials take place in Sacramento, California yet there are over 37 thousand locations conducting such research."
What possible risks might be associated with using Pembrolizumab?
"There is clinical evidence that implies the safety of Pembrolizumab, resulting in it receiving a score of 2. However, no data has been collected pertaining to its efficacy at this time."
Share this study with friends
Copy Link
Messenger